株式会社日本シノバイオロジカル Product Lineup

The kallikrein-related peptidases (KLK) family, consisting of 15 homologous serine proteases (KLK1 to KLK15), plays a crucial role in various physiological and pathological processes. Notable KLKs, including KLK3, KLK5, KLK6, KLK10, and KLK14, demonstrate significant effects on the regulation of cancer onset, proliferation, migration, invasion, and chemotherapy resistance, influencing complex molecular networks associated with the survival and dissemination of cancer cells. The functional relevance of KLKs in cancer progression has made them important biomarkers and therapeutic targets in various cancers. In translational medicine, KLK1, KLK2, KLK3, KLK5, KLK7, KLK14, and KLKB1 are utilized in the design of KLK-targeted therapies, showing promise for the treatment of cancer, neurological disorders, skin diseases, and other medical fields. Sino Biological is committed to advancing drug development targeting KLKs, offering a comprehensive selection of recombinant KLK proteins and corresponding antibodies for isoform mapping, ELISA measurements, and the identification of kallikreins that are highly expressed in specific carcinomas.

• Other research reagents

The paper-based technology known as lateral flow assay (LFA) is widely used for qualitative and quantitative analysis of complex mixtures. When a sample is added to the testing device, results are displayed quickly without the need for extensive sample preprocessing or complex laboratory investigations and equipment. LFA offers significant advantages over traditional analytical methods, including affordability, user-friendly operation, and easy visual interpretation, providing a cost-effective solution for the detection of various analytes. Sino Biological confidently offers validated antibody pairs with picogram sensitivity for LFA to support your research and save time. These antibodies are specifically designed to detect a variety of targets, including: • Viral antigens (Monkeypox, Influenza A and B, and RSV) • Cytokines (Human IL-2, IL-6, IL-8, IL-17, and TNF) • Cancer biomarkers (Human CEA, CEACAM5, and AFP)

• Other research reagents

The influenza virus is an RNA virus that causes acute respiratory diseases and outbreaks in human populations due to its strong infectivity. According to the WHO, influenza results in approximately 1 billion infections and about 290,000 to 650,000 deaths worldwide each year. Vaccination is the most effective strategy to prevent influenza virus infection and its severe complications. However, the influenza virus is prone to mutation, and the circulating strains vary from year to year. Each year, vaccine manufacturers develop and produce influenza vaccines based on the strains recommended by the WHO. Our company provides comprehensive influenza vaccine development services and production solutions to vaccine manufacturers. We offer a wide range of research reagents for influenza viruses, including influenza vaccine antigens, antibody pairs, neutralizing antibodies, and kits. Additionally, we provide high-quality technical services such as kit development, antigen expression, and antibody development. These products and services are suitable for various vaccine development scenarios, including screening of vaccine candidate strains, preparation of virus seed batches, evaluation of vaccine safety and immunogenicity, and assessment of vaccine protective effects.

• Other research reagents

We will deliver new products from various fields.

• others

Our company has delivered products using advanced technology platforms to many researchers around the world as a supplier of bio-reagents and related contract services. With the establishment of our Japanese subsidiary, we will provide high-quality research reagents such as recombinant proteins and antibodies, as well as contract services, to domestic researchers at competitive prices. We will continue to support life sciences research and drug discovery research in Japan. 【Business Contents】 ■ Recombinant Proteins ■ Poly/Monoclonal Antibodies ■ cDNA Clones ■ ELISA Kits ■ Contract Services *For more details, please refer to the PDF document or feel free to contact us.

• Other contract services

Introducing the "Virus Antigen Bank" of Shinobiological Co., Ltd. We offer over 1,100 recombinant virus antigens, including 50 types of virus antigens and antigens derived from more than 380 strains. Additionally, we have over 6,000 virus-related reagents, including ELISA Kits, which are widely used by researchers around the world for the development of vaccines, immunodiagnostic agents, and therapeutic antibodies. [Details] ■ Recombinant proteins of virus antigens - Derived from 380+ strains - 1,100+ virus antigens ■ Virus antibodies - 500+ antibodies - 20+ neutralizing antibodies *For more details, please refer to the PDF document or feel free to contact us.

• others

We would like to introduce the "over 14,000 elite antibodies" handled by Shinobiological Co., Ltd. These antibodies have been validated for a wide range of applications, including ELISA, WB, FCM, IHC, IF, IP, and neutralization tests. They possess high affinity and specificity. We offer various antibodies, such as "IHC antibodies for biomarker testing," which guarantee reliability and reproducibility through a rigorous quality control system. 【Features】 ■ High affinity ■ High specificity ■ High sensitivity ■ High neutralization activity *For more details, please refer to the PDF document or feel free to contact us.

• others

We would like to introduce the "recombinant proteins" handled by Shinobiological Co., Ltd. Over 85% of our protein products are expressed in eukaryotic cells. They are similar in structure and modifications to the original proteins. We offer a wide variety of products derived from numerous species, multiple tags, and disease variants, with bulk production capabilities allowing for production in units of up to several kilograms. 【Features】 ■ Over 85% of our protein products are expressed in eukaryotic cells ■ A rich variety of products derived from numerous species, multiple tags, and disease variants ■ Bulk production capabilities allowing for production in units of up to several kilograms *For more details, please refer to the PDF document or feel free to contact us.

• others